Check for updates

#### **OPEN ACCESS**

EDITED BY Rupert Ortner, g.tec medical engineering GmbH, Austria

REVIEWED BY Zhen Yuan, University of Macau, China Valentina Azzollini, University of Pisa, Italy Hewei Wang, Fudan University, China

\*CORRESPONDENCE Jingui Wang ⊠ wjg65tj@163.com

RECEIVED 27 May 2024 ACCEPTED 30 October 2024 PUBLISHED 27 November 2024

#### CITATION

Wang X, Yin L, Wang Y, Zhang H, Zhang S, Wu J, Fan S, Li Z, Li H and Wang J (2024) Transcutaneous electrical acupoint stimulation for upper limb motor recovery after stroke: a systematic review and meta-analysis. *Front. Aging Neurosci.* 16:1438994. doi: 10.3389/fnagi.2024.1438994

#### COPYRIGHT

© 2024 Wang, Yin, Wang, Zhang, Zhang, Wu, Fan, Li, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Transcutaneous electrical acupoint stimulation for upper limb motor recovery after stroke: a systematic review and meta-analysis

Xiaoyu Wang<sup>1,2,3</sup>, Lianjun Yin<sup>4</sup>, Yikun Wang<sup>1,2</sup>, Haining Zhang<sup>1,2</sup>, Shiying Zhang<sup>1,2</sup>, Jiantong Wu<sup>1,2</sup>, Shun Fan<sup>1,2</sup>, Zhengfei Li<sup>1,2</sup>, Huanan Li<sup>1,2,3</sup> and Jingui Wang<sup>1,2,3</sup>\*

<sup>1</sup>Department of Tuina, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, <sup>2</sup>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China, <sup>3</sup>The Institute of Traditional Chinese Medicine Massage of Tianjin Health Commission, Tianjin, China, <sup>4</sup>Rehabilitation Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China

**Background:** Transcutaneous electrical acupoint stimulation (TEAS) is an innovative, non-invasive therapy that stimulates the contraction of paralyzed muscles in the upper limbs, promoting functional recovery. Several studies have demonstrated the efficacy of TEAS in restoring upper limb function. This study aims to evaluate the impact of TEAS on upper limb motor recovery after stroke.

**Objectives:** This study aims to evaluate the influence of TEAS on upper limb motor recovery after stroke and improve the quality of life in such patients.

**Methods:** Eight databases were systematically searched from inception to 1st October 2024. Two independent reviewers conducted the screening and data extraction of the study. The primary outcome measure was the Fugl Meyer Assessment of the Upper Extremity (FMA-UE), which evaluates upper extremity motor function in stroke patients. Secondary outcomes included the Modified Ashworth Scale (MAS) for assessing spasticity and the Modified Barthel Index (MBI) to evaluate patients' abilities to perform activities of daily living. Data synthesis was conducted using RevMan 5.4 and Stata 14.0. The GRADE method was employed to assess the quality of evidence.

**Results:** A total of 16 trials involving 1,218 stroke patients were included in this meta-analysis. Meta-analysis showed that the TEAS significantly improved upper limb function (SMD = 1.70, 95Cl% = 1.09 to 2.31, *p* < 0.00001, *l*<sup>2</sup> = 93%; low certainty of evidence), reduced spasticity (SMD = -1.18, 95Cl% = -1.79 to -0.58, *p* < 0.00001, *l*<sup>2</sup> = 90%; very low certainty of evidence), and enhanced the ability to perform daily activities (SMD = 1.53, 95Cl% = 0.85 to 2.20, *p* < 0.00001, *l*<sup>2</sup> = 95%; low certainty of evidence).

**Conclusion:** Our results indicated that TEAS improved motor function and functional activities and reduced muscle tone in the upper limbs after stroke. However, these results should be interpreted with caution due to the limited strength of the evidence. High-quality, larger sample, multi-center studies are needed to validate these preliminary findings.

**Systematic review registration:** This study was registered on PROSPERO with registration number CRD42024592509. https://www.crd.york.ac.uk/prospero/ display\_record.php?ID=CRD42024592509

#### KEYWORDS

transcutaneous electrical acupoint stimulation (TEAS), stroke, upper limb function, meta-analysis, systematic review

# **1** Introduction

Stroke is a condition characterized by damage to brain tissue caused by the rupture or obstruction of blood vessels within the brain (Sacco et al., 2013). According to the Global Burden of Disease Study (GBD), stroke ranks as the third leading cause of disability and mortality, accounting for 87.4 deaths (95% UI 79.5–94.4) per 100,000 population (GBD 2021 Causes of Death Collaborators, 2024). In China alone, more than 70 million individuals are affected by stroke, making it the leading cause of death in the country. Furthermore, as the population continues to age, the burden associated with stroke is expected to increase significantly (Tu and Wang, 2023; Wang et al., 2022).

After the onset of stroke, a variety of adverse manifestations can occur rapidly, most often accompanied by sensory and limb dysfunction, which severely impacts patients' daily lives (Dawson et al., 2021). Studies have shown that approximately 55–75% of patients experience varying degrees of upper limb motor dysfunction (Ma et al., 2021). Relevant studies have demonstrated a strong correlation between upper limb motor function and activities of daily living (ADL) in stroke patients, which places a significant burden on caregivers, families, and society (Meng et al., 2022).

Upper limb motor dysfunction resulting from damage to upper motor neurons is characterized by poor motor ability, spasticity and flexion of the fingers, and impaired fine motor control of the hand (Zhou et al., 2021). Compared to lower limb motor dysfunction after a stroke, upper limb motor dysfunction is more difficult to recover from, with a higher incidence and a longer recovery period (Julie et al., 2017). Because fine motor tasks, especially those involving the hand, require precision, regaining normal function is challenging, and relying solely on traditional rehabilitation training often yields unsatisfactory outcomes.

Neurorehabilitation for upper limb dysfunction has become a central focus of post-stroke recovery efforts (Huang et al., 2024; Tang et al., 2024). Based on insights into brain functional remodeling, brain functional connectivity, cortical reorganization, and neural plasticity, various rehabilitation methods have been developed (Muller et al., 2024). Some of these methods, such as robotic exoskeleton training and constraint-induced movement therapy, have shown significant effectiveness (Zhang et al., 2022; Thrane et al., 2015).

Constraint-induced movement therapy, in particular, has shown positive rehabilitation outcomes for patients with acute or subacute strokes (Liu et al., 2017). However, for stroke survivors with severe motor deficits, the treatment outcomes are often minimal, and recovery remains unpredictable (Coscia et al., 2019).

Robotic training may be a viable alternative for patients with severe upper limb injuries, though the high cost of robotic devices poses a challenge (Zhang et al., 2022). Other therapeutic techniques, such as mirror therapy (Nogueira et al., 2021) and neurodevelopmental treatment (Langhammer and Stanghelle, 2011), appear to lack strong evidence supporting their effectiveness in improving upper limb motor function after a stroke. Therefore, new rehabilitation methods should be developed to enhance upper limb motor function impairment following a stroke (Pollock et al., 2014).

Electrical stimulation therapy for post-stroke spasticity has become a major area of interest. The American Heart Association guidelines for adult stroke rehabilitation endorse neuromuscular electrical stimulation as an effective approach for the transient alleviation of spasticity (Winstein et al., 2013). Transcutaneous electrical acupoint stimulation (TEAS) is a non-invasive stimulation therapy that combines the advantages of Chinese acupuncture and transcutaneous electrical nerve stimulation (Pan et al., 2023). TEAS uses low-frequency pulsed direct current to electrically stimulate peripheral acupoints and surrounding tissues. This stimulation facilitates the transmission of information to the central nervous system, thereby enhancing local neuromuscular function (Szmit et al., 2023).

TEAS mimics the effects of acupuncture on specific acupoints, stimulating muscle cell activity and facilitating the restoration of upper limb function and active control capabilities as swiftly as possible. This approach effectively alleviates symptoms of spasticity (Yan and Hui-Chan, 2009). Moreover, it activates relevant regions of the cerebral cortex, eliciting responses from neurons associated with the upper limb. This process is beneficial for enhancing muscle strength and improving hand coordination (Alwhaibi et al., 2021). Compared to electroacupuncture and traditional acupuncture, TEAS can avoid discomforts such as pain and bleeding and has higher patient compliance (Chi et al., 2019). In addition, the input time and frequency of the pulse current can be set after setting the parameters, facilitating the quantification and standardization of acupuncture treatment (Xu et al., 2016).

Clinical practice has confirmed that combined rehabilitation training with TEAS can significantly enhance patients' muscle strength and improve hand function, grip strength, and manual dexterity. This approach facilitates the recovery of upper limb functionality while alleviating pain and addressing symptoms such as muscle spasms, ultimately enhancing the patient's quality of life (Wang, 2024). In addition, previous network meta-analysis showed that TEAS had the most significant effect on upper limb motor recovery in stroke (Tang et al., 2021). Factors such as the treatment regimen and TEAS parameters should be considered to accurately measure the effectiveness of TEAS. However, no comprehensive metaanalysis has included the above factors simultaneously to specifically analyze the effects of TEAS on upper limb motor recovery in stroke. In this systematic review, stratified analysis was conducted to summarize and analyze the scientific evidence of TEAS on upper limb motor recovery in stroke patients.

# 2 Methods

A systematic review and meta-analysis were conducted according to the reporting checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (Page et al., 2021). The study has been registered with Prospero (registration number CRD42024592509). Ethics review board approval was not required for this study.

### 2.1 Search strategy

Two reviewers (LJY and XYW) independently searched databases to collect randomized controlled trials (RCTs) of TEAS on upper limb motor recovery in stroke patients, including eight databases: 4 English databases, Embase, Web of Science, PubMed, The Cochrane Library and 4 Chinese databases: China National Knowledge Infrastructure (CNKI), Wanfang database (WANFANG), VIP database (VIP) and Chinese Biomedical Literature Service system (CBM). The search period covered from the inception of each database to 1st October 2024, and references from the included literature were traced. The languages are Chinese and English. In addition, the key points used in this study include "transcutaneous electrical acupoint stimulation," "TEAS," "stroke," "cerebrovascular accident," "cerebrovascular disease," "upper limb motor," "upper limb," "randomized controlled trials," and "clinical trial." The specific search strategies are described in the **Supplementary Appendix**.

### 2.2 Eligibility criteria

Studies were eligible for inclusion if they met the following criteria: (1) Study designs: randomized controlled trials; (2) Participants: The selected stroke patients should meet the diagnostic criteria of stroke published in the literature or recognized at home and abroad and be further diagnosed by CT and MRI. The patient had stable vital signs, clear consciousness, and upper limb motor dysfunction. There were no restrictions based on gender, age, or race. (3) Intervention: TEAS stimulation (the acupoints, frequency, duration, and course of TEAS stimulation were not limited); (4) Comparison: sham TEAS treatment or conventional rehabilitation treatment; (5) Outcomes: the primary outcome measure was Fugl Meyer Assessment of the upper extremity (FMA-UE), and the secondary outcome measures were Modified Ashworth Scale (MAS) and Modified Barthel Index (MBI). The FMA-UE is the most commonly used instrument for assessing upper limb motor function in stroke patients and has demonstrated good reliability and validity. Spasticity was measured using the Modified Ashworth Scale (MAS), and the Modified Barthel Index (MBI) was used to evaluate the patient's ability to perform daily activities.

The exclusion criteria were as follows: (1) conferences and abstract papers; (2) unable to obtain the full text or extract relevant outcome indicators; (3) non-adult patients with stroke; (4) case reports, protocol studies, reviews, and meta-analysis; (5) duplicate published studies; (6) the number of study cases was less than 10; and (7) intervention measures, grouping methods and effect indicators were not consistent.

### 2.3 Study selection and data extraction

Two researchers (WXY and YLJ) independently audited the literature and extracted data. Endnote 20.1 software was used to eliminate duplicate records. Studies that did not meet the criteria were

screened by reading titles and abstracts. Finally, the full text was read, the final literature was determined according to the inclusion and exclusion criteria, and the data were extracted. The extracted data were entered into RevMan 5.4 and double-checked for accuracy. If there was any disagreement, the third researcher (WYK) discussed and made a decision. The extracted contents mainly included the name of the first author, the year of publication, the characteristics of participants (age and sample size), the details of TEAS (acupoint selection, frequency, and intervention time), the control intervention, the content of quality assessment (randomized method, blind method, selection report, complete results, and so on), and the data of related outcome indicators.

### 2.4 Risk of bias assessment

Two reviewers (WXY and ZHN) independently used the Cochrane Collaboration tool to assess the risk of bias in the selected trials (Higgins et al., 2011). The evaluation included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. The risk assessment results included high risk, low risk, and unclear. When there were differences in opinions between the two evaluators, they were discussed and resolved first. If the opinions differed, a third evaluator (ZSY) would re-evaluate the results to achieve consistency.

### 2.5 Data synthesis and statistical analysis

Statistical analysis was performed using Review Manager 5.4 and Stata 14.0 software. The outcome indicators involved in this study were all continuous variables. The effect value index was expressed as standard mean difference (SMD), and the 95% confidence interval of each effect value was calculated. If  $p \ge 0.10$ ,  $I^2 \le 50\%$ , there was no heterogeneity or small heterogeneity among the studies, so the fixed effect model was used. If p < 0.1,  $I^2 > 50\%$ , the heterogeneity among the studies was considered large, so the random effect model was used (Higgins and Thompson, 2002), and the source for heterogeneity was searched through sensitivity analysis and subgroup analysis. A p-value of <0.05 was considered statistically significant. According to the control methods (no TEAS and sham TEAS) and TEAS parameters (including frequency, treatment duration, and retention time) for subgroup analysis. If sufficient trials ( $\geq 10$  trials) were included, publication bias was assessed using funnel plots and Egger's test (Egger et al., 1997).

### 2.6 Evidence quality evaluation

The quality of evidence for each outcome was assessed using the Grading of Recommendations Assessment, Development, and Evaluations (GRADE) system. Based on factors such as methodological quality, consistency of results across studies, directness of evidence, precision of evidence, and possibility of publication bias, the evidence level of included RCTs was judged to be downgraded. The quality of evidence was categorized into high, medium, low, or very low (Guyatt et al., 2008). Two researchers conducted the assessments and

cross-checked the results. Any disagreement was resolved by consensus. Any disagreements were resolved through consensus, and if consensus could not be reached, a third researcher was consulted.

# **3** Results

### 3.1 Study selection

We conducted a thorough search of the aforementioned eight databases following our inclusion and exclusion criteria, initially identifying 1,030 articles. After removing duplicates, 332 articles remained in the database. By reviewing the titles and abstracts, we excluded those that did not meet our inclusion criteria, resulting in 41 articles remaining for further consideration. Upon examining the full texts of these articles, we excluded an additional 25 articles. Finally, 16 RCTs (Chao, 2016; Chen et al., 2015; Chen et al., 2019a; Chen et al., 2019b; Gu et al., 2019; Jia et al., 2018; Mao et al., 2017; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2020; Zheng and Mao, 2020) were included. The flow chart and results of the literature screening are shown in Figure 1.

### 3.2 Study characteristics

The characteristics of the 16 trials included are summarized in Table 1.

A total of 16 trials involving 1,218 stroke patients (10 dropouts) were included in this meta-analysis, with 603 in the TEAS group and 605 in the control group. The trials were published between 2015 and 2023. Sample sizes ranged from 31 to 204. The sample included 431 women and 777 men. As described in the included trials, except for one trial (Yan et al., 2019), which did not report the type of stroke, the remaining trials included 377 patients with intra-cerebral hemorrhage and 712 patients with cerebral infarction. A total of 10 trials (Chen et al., 2015; Chen et al., 2019a; Chen et al., 2019b; Jia et al., 2018; Mao et al., 2017; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Zheng and Mao, 2020) specified Brunstrom stages. Moreover, three trials (Chen et al., 2015; Peng et al., 2015; Wang H. et al., 2023) used sham TEAS as the control group. The duration of treatment ranged from 21 to 120 days. The outcome measures included the FMA-UE, MAS, and MBI. A total of 13 trials (Chao, 2016; Chen et al., 2015; Chen et al., 2019b; Mao et al., 2017; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Yang, 2023; Zheng and Mao, 2020) used FMA-UE as an outcome measure, seven trials (Chen et al., 2015; Chen et al., 2019b; Gu et al., 2019; Mao et al., 2017; Wang H. et al., 2023; Yang, 2023; Zheng and Mao, 2020) used MAS, and 11 trials (Chen et al., 2015; Chen et al., 2019a; Chen et al., 2019b; Jia et al., 2018; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Xie et al., 2019; Yan et al., 2019; Yu et al., 2020) used MBI.

### 3.3 TEAS regimen

The details of TEAS for the included 16 trials are summarized in Table 2. For stimulation frequencies, 100 Hz and 2 Hz were popular

across trials. The most commonly used acupoints were LI10 (Shousanli) and TE5 (Waiguan), used in 13 trials. The most commonly used treatment duration was 30 min (78.5%). The most commonly used frequency of treatment was 5 times per week (66.7%).

### 3.4 Risk of bias


A total of 14 (Chao, 2016; Chen et al., 2015; Chen et al., 2019a; Chen et al., 2019b; Gu et al., 2019; Jia et al., 2018; Mao et al., 2017; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Xie et al., 2019; Yang, 2023; Yu et al., 2020; Zheng and Mao, 2020) trials described detailed methods of randomization, except for two trials (Peng et al., 2015; Yan et al., 2019) in which the risks were not clear. Only two trials (Wang H. et al., 2023; Xie et al., 2019) emphasized allocation concealment. Two trials (Peng et al., 2015; Xie et al., 2019) performed a blinding method on subjects and operators as high-risk, and only two trials (Chen et al., 2019a; Chen et al., 2019b) performed blinding to outcome assessment. One trial (Yan et al., 2019) was conducted as an unclear risk due to incomplete outcome data. In addition, three trials (Gu et al., 2019; Jia et al., 2018; Yan et al., 2019) had unclear selective reporting bias, and four trials (Chao, 2016; Chen et al., 2019a; Mao et al., 2017; Yan et al., 2019) reported other biases. The risk of bias is summarized in Figure 2.

### 3.5 Meta-analysis

### 3.5.1 Fugl Meyer Assessment of the Upper Extremity (FMA-UE)

A total of 13 RCTs (Chao, 2016; Chen et al., 2015; Chen et al., 2019b; Mao et al., 2017; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Yang, 2023; Zheng and Mao, 2020) involving 865 patients reported FMA-UE. There was a significant difference in FMA-UE in the TEAS group (SMD = 1.70, 95CI% = 1.09 to 2.31, p < 0.00001,  $I^2 = 93\%$ ; Figure 3), although the quality of evidence was low (Table 3). The results of subgroup analysis showed that TEAS had a statistically significant effect on improving FMA-UE compared with no TEAS (Figure 4) (SMD = 1.76, 95CI% = 1.22 to 2.30, p < 0.00001,  $I^2 = 86\%$ ; Table 4), while there was no significant statistical difference compared with sham TEAS (SMD = 1.54, 95CI% = 0.00 to 3.09, p = 0.05,  $I^2 = 96\%$ ; Table 4).

In addition, we also performed the subgroup analysis of the TEAS parameters (Figure 5). In the subgroup analysis of frequency of TEAS (Figure 5A), there was a statistically significant difference between the 5 times per week, and 6 times per week TEAS treatment (SMD = 1.57, 95CI% = 0.92 to 2.22, p < 0.00001,  $I^2 = 92\%$ ; SMD = 2.43, 95CI% = 1.67 to 3.19, p < 0.00001; Table 4), while there was no significant difference between TEAS treatment once a day (SMD = 1.82, 95CI% = -0.13 to 3.77, p = 0.07,  $I^2 = 97\%$ ; Table 4). Subgroup based on the treatment duration (Figure 5B): 0–4 weeks, 5–8 weeks, and more than 8 weeks, TEAS was superior to the control group in improving FMA-UE (SMD = 2.09, 95CI% = 1.33 to 2.86, p < 0.00001,  $I^2 = 92\%$ ; SMD = 1.01, 95CI% = 0.60 to 1.42, p < 0.00001; SMD = 0.35, 95CI% = 0.06 to 0.63, p = 0.02; Table 4).



Furthermore, in the subgroup analysis of retention time (Figure 5C), TEAS was superior to the control group in improving FMA-UE either less than 30 min or more than 30 min (SMD = 2.58, 95CI% = 1.68 to 3.49, p < 0.00001,  $I^2 = 80\%$ ; SMD = 1.50, 95CI% = 0.83 to 2.16, p < 0.0001,  $I^2 = 92\%$ ; Table 4).

#### 3.5.2 Modified Ashworth Scale (MAS)

A total of 7 RCTs (Chen et al., 2015; Chen et al., 2019b; Gu et al., 2019; Mao et al., 2017; Wang H. et al., 2023; Yang, 2023; Zheng and Mao, 2020) reported MAS in a total of 552 patients. Meta-analysis results show that compared with the control group, the TEAS group had significant improvement in MAS (SMD = -1.18, 95CI% = -1.79 to -0.58, p < 0.00001,  $I^2 = 90\%$ ; Figure 6), although the quality of evidence was very low (Table 3). The results of subgroup analysis showed that TEAS had significant advantages in improving MAS compared with no TEAS and sham

TEAS (Figure 7) (SMD = -1.34, 95CI% = -2.03 to -0.65, p = 0.0001,  $I^2 = 88\%$ ; SMD = -0.36, 95CI% = -0.65 to -0.08, p = 0.01; Table 4).

We performed the subgroup analysis of the TEAS parameters (Figure 8). In the subgroup analysis of the frequency of TEAS (Figure 8A), once a day and 5 times per week had statistical significance in the evaluation of MAS (SMD = -1.68, 95CI% = -3.23 to -0.13, p=0.03,  $I^2=91\%$ ; SMD = -1.01, 95CI% = -1.74 to -0.28, p=0.007; Table 4). Subgroup analysis based on the treatment duration (Figure 8B): 0-4 weeks, 5-8 weeks, and more than 8 weeks, TEAS was superior to the control group in improving MAS (SMD = -1.51, 95CI% = -2.30 to -0.71, p=0.0002,  $I^2=89\%$ ; SMD = -0.56, 95CI% = -1.11 to -0.01, p=0.04; SMD = -0.36, 95CI% = -0.65 to -0.08, p=0.01; Table 4). Furthermore, in the subgroup analysis of retention time (Figure 8C), TEAS for less than 30 min or more than 30 min was superior to the control group in improving MAS

Study	Type of stroke (ICH/ CI)	Brunnstrom	Course of disease (days)	Sample size	Age (years)	Gender (M/F)	Interve I	ention C	Duration (days)	Outcome
Yang (2023)	I: (19/30) C: (17/32)	1	I: 161.4±15.6 C: 162.6±16.2	98	I: 68.49±2.83 C: 68.51±2.86	I: (25/24) C: (27/22)	TEAS + CR	CR	28	FMA-UE, MAS
Wang D. et al. (2023)	I: (34/68) C: (31/71)	I/V	/	204	I: 60.6±12.5 C: 61.9±10.5	I: (77/25) C: (72/30)	TEAS + CR	Sham TEAS + CR	72	FMA-UE, MBI, MAS
Xia et al. (2021)	I: (15/9) C: (12/12)	II/V	I: 35±18.06 C: 36.4±17.99	48	I: 56.2±9.91 C: 56.5±7.9	I: (17/7) C: (18/6)	TEAS + CR	CR	28	FMA-UE, MBI
Zheng and Mao (2020)	I: (15/19) C: (13/21)	I/V	I: 186±54 C: 177±21	68	I: 58.9±1.3 C: 58.8±1.1	I: (23/11) C: (22/12)	TEAS + CR	CR	28	FMA-UE, MAS
Yu et al. (2020)	I: (24/30) C: (22/32)	/	/	108	I: 62.5±6.5 C: 61.8±5.8	I: (30/24) C: (29/25)	TEAS + CR	CR	30	MBI
Chen et al. (2019a)	I: (5/23) C: (9/19)	< V	I: 152.39±123.46 C: 156.36±123.60	60 (Fall off 4 cases)	I: $64.50 \pm 12.95$ C: $64.57 \pm 9.35$	I: (22/6) C: (21/7)	TEAS + CR	CR	42	FMA-UE, MBI
Gu et al. (2019)	I: (6/15) C: (8/13)	1	1	42	I: 63.8±7.1 C: 62.9±8.3	I: (14/7) C: (12/9)	TEAS + CR	CR	28	FMA-UE, MAS
Xie et al. (2019)	I: (CI:42) C: (CI:40)	1	I: 40.28±9.28 C: 41.95±10.88	82	I: $50.38 \pm 10.76$ C: $49.68 \pm 10.52$	I: (23/19) C: (24/16)	TEAS + CR	CR	28	FMA-UE, MBI
Yan et al. (2019)	1	1	/	120	I: 62.40 C: 60.90	I: (33/27) C: (39/21)	TEAS + CR	CR	120	MBI
Chen et al. (2019b)	I: (8/18) C: (6/21)	III/V	I: 275.95±59.11 C: 271.43±74.01	53	I: $60.75 \pm 16.62$ C: $60.45 \pm 11.25$	I: (19/7) C: (20/7)	TEAS + CR	CR	42	FMA-UE, MBI, MAS
Jia et al. (2018)	I: (22/32) C: (20/34)	I/V	I: 144±51 C: 150±48	108	I: 64.7±9.8 C: 64.2±9.5	I: (29/25) C: (32/22)	TEAS + CR	CR	84	MBI
Mao et al. (2017)	I: (12/14) C: (11/15)	I/V	I: 177.60±72.00 C: 186.90±96.30	52	I: 59.52±7.35 C: 58.92±6.21	I: (14/12) C: (18/8)	TEAS + CR	CR	28	FMA-UE, MAS
Chao (2016)	I: (17/10) C: (12/16)	1	I: 161.4±104.1 C: 169.2±101.7	55	I: $52.26 \pm 15.56$ C: $49.54 \pm 11.21$	I: (22/5) C: (24/4)	TEAS + CR	Sham TEAS + CR	28	FMA-UE, MBI
Peng et al. (2015)	I: (7/14) C: (7/13)	< V	I: 67.5±26.1 C: 60.6±31.5	46 (Fall off 5 cases)	I: 66.4±10.8 C: 65.5±11.2	I: (9/12) C: (10/10)	TEAS + CR	Sham TEAS + CR	21	FMA-UE, MBI
Chen et al. (2015)	I: (7/13) C: (8/15)	I/V	I: 186.00±85.50 C: 185.10±92.40	43	I: 61.05±9.24 C: 57.69±8.79	I: (17/3) C: (19/4)	TEAS + CR	CR	28	FMA-UE, MBI, MAS
Tang et al. (2015)	I: (4/11) C: (6/10)	I/II	I: 40.23±16.02 C: 37.64±18.32	31	I: 54.69±9.68 C: 57.93±11.2	I: (12/3) C: (14/2)	TEAS + CR	CR	42	FMA-UE, MBI

#### TABLE 1 Characteristics of the included studies.

I, Intervention group; C, Control group; ICH, Intra Cerebral Hemorrhage; CI, Cerebral Infarction; M, Male; F, Famale; /, not mention; CR, Conventional Rehabilitation; TEAS, Transcutaneous electrical acupoint stimulation; FMA-UE, Fugl-Meyer Assessment of the upper extremity; MAS, Modified Ashworth Scale; MBI, Modified Barthel Index.

Study	Frequency (Hz)/ intensity (mA) of electrical stimulation	The site of electrical stimulation	Duration of treatments	Number of treatments	Frequency (weeks/days)
Yang (2023)	35 Hz/10/50 mA	LI10 (Shousanli), TE5 (Waiguan)	15 min	TEAS + CR: 28 CR: 28	Once a day
Wang D. et al. (2023)	2 Hz	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 30 Sham TEAS + CR: 30	5 times per week
Xia et al. (2021)	100 Hz/100 mA	LI15 (Jianyu), LI11 (Quchi), LI10 (Shousanli), TE5 (Waiguan)	20 min	TEAS + CR: 24 CR: 24	6 times per week
Zheng and Mao (2020)	1	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 34 CR: 34	5 times per week
Yu et al. (2020)	100 Hz/10/40 mA	Eight evil points	30 min	TEAS + CR: 54 CR: 54	Once a day
Chen et al. (2019a)	Brunnstrom I ~ II: 2 Hz, Brunnstrom III ~ IV: 4/15 Hz	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 28 CR: 28	5 times per week
Gu et al. (2019)	35 Hz/10/50 mA	LI10 (Shousanli), TE5 (Waiguan)	15 min	TEAS + CR: 21 CR: 21	Once a day
Xie et al. (2019)	2 Hz	TE5 (Waiguan), L115 (Jianyu), L111 (Quchi), L110 (Shousanli)	30 min	TEAS + CR: 42 CR: 40	5 times per week
Yan et al. (2019)	General condition: 10 Hz, The disease is serious: 4 Hz	LI10 (Shousanli), TE5 (Waiguan)	30 min	CT + TEAS: 60 CT: 60	1
Chen et al. (2019b)	Brunnstrom III ~ IV: 10/15 Hz Brunnstrom V: 4 Hz	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 26 CR: 27	5 times per week
Jia et al. (2018)	Brunnstrom I/II: 2 Hz, Brunnstrom III/IV: 4/15 Hz, Brunnstrom V/VI: 4 Hz	LI10 (Shousanli), TE5 (Waiguan)	Brunnstrom I/II: 25/30 min, Brunnstrom III/IV: 20/30 min, Brunnstrom V/VI: 30 min	TEAS + CR: 54 CR: 54	5 times per week
Mao et al. (2017)	1	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 26 CR: 26	5 times per week
Chao (2016)	100 Hz/10/40 mA	Eight evil points	30 min	TEAS + CR: 28 Sham TEAS + CR: 28	Once a day
Peng et al. (2015)	100 Hz	TE5 (Waiguan), L115 (Jianyu), L111 (Quchi), L114 (Hegu)	30 min	TEAS + CR: 21 Sham TEAS + CR: 20	5 times per week
Chen et al. (2015)	/	LI10 (Shousanli), TE5 (Waiguan)	1	TEAS + CR: 20 CR: 23	5 times per week
Tang et al. (2015)	1	LI10 (Shousanli), TE5 (Waiguan)	30 min	TEAS + CR: 30 CR: 30	5 times per week

#### TABLE 2 Details of transcutaneous electrical acupoint stimulation in included trials.

CR, Conventional Rehabilitation; TEAS, Transcutaneous electrical acupoint stimulation; /, not mention.


 $(SMD = -1.68, 95CI\% = -3.23 \text{ to } -0.13, p = 0.03, I^2 = 91\%; SMD = 1.09, 95CI\% = 2.00 \text{ to } 0.17, p = 0.02, I^2 = 93\%; Table 4).$ 

### 3.5.3 Modified Barthel Index (MBI)

A total of 11 RCTs (Chen et al., 2015; Chen et al., 2019a; Chen et al., 2019b; Jia et al., 2018; Peng et al., 2015; Tang et al., 2015; Wang H. et al., 2023; Xia et al., 2021; Xie et al., 2019; Yan et al., 2019; Yu et al., 2020) involving 886 patients reported MBI. Meta-analysis results

showed that compared with the control group, the TEAS group had significant differences in MBI (SMD=1.53, 95CI%=0.85 to 2.20, p < 0.00001,  $I^2 = 95\%$ ; Figure 9), although the quality of evidence was low (Table 3).

Subgroup analysis results show that, compared with no TEAS (Figure 10), TEAS was statistically different in improving the MBI. (SMD = 1.52, 95CI % = 0.84 to 2.21, p < 0.0001,  $I^2 = 93\%$ ; Table 4), although there was no significant statistical difference compared with



	1	EAS		C	ontrol		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen 2015	-1.22	0.5	20	-0.87	0.46	23	14.0%	-0.72 [-1.34, -0.10]	
Chen 2019b	-0.88	0.78	26	-0.44	0.76	27	14.4%	-0.56 [-1.11, -0.01]	+
Gu 2019	-2.6	0.32	21	-1.6	0.45	21	12.5%	-2.51 [-3.34, -1.69]	-
Mao 2017	-1.21	0.49	26	-0.84	0.44	26	14.3%	-0.78 [-1.35, -0.22]	
Wang 2023	-0.77	0.73	99	-0.52	0.63	97	15.8%	-0.36 [-0.65, -0.08]	•
Yang 2023	-3.2	0.33	49	-2.9	0.31	49	15.2%	-0.93 [-1.35, -0.51]	+
Zheng 2020	-1.21	0.08	34	-0.84	0.17	34	13.6%	-2.75 [-3.43, -2.08]	+
Total (95% CI)			275			277	100.0%	-1.18 [-1.79, -0.58]	•
Heterogeneity: Tau <sup>2</sup> :	= 0.58; C	hi² = 5	8.94, dt	= 6 (P <	< 0.00	001); I <sup>z</sup>	= 90%		
Test for overall effect	: Z = 3.84	(P = 0	).0001)						-10 -5 0 5 10 Favours [TEAS] Favours [Control]
URE 3									
est plot and meta-and	alysis of I	FMA-L	JE.						

sham TEAS (SMD = 1.61, 95CI% = -1.59 to 4.81, p = 0.32,  $I^2 = 98\%$ ; Table 4).

In addition, we performed a subgroup analysis of the TEAS parameters (Figure 11). In the subgroup analysis of frequency of TEAS (Figure 11A), TEAS treatment administered once a day, 5 times per week, and 6 times per week showed statistical significance in the evaluation of MBI (SMD=0.51, 95CI%=0.13 to 0.90, p=0.009; SMD=1.48, 95CI%=0.58 to 2.37, p=0.001,  $I^2$ =95%; SMD=3.67, 95CI%=2.72 to 4.62, p<0.00001; Table 4). Subgroup based on the

treatment duration (Figure 11B): 0-4 weeks, 5-8 weeks, and more than 8 weeks, TEAS was superior to the control group in improving MBI (SMD = 2.53, 95CI% = 0.54 to 4.52, p = 0.01,  $I^2 = 95\%$ ; SMD = 1.17, 95CI% = 0.39 to 1.94, p = 0.003,  $I^2 = 88\%$ ; SMD = 2.18, 95CI% = 1.03 to 3.32, p = 0.0002,  $I^2 = 92\%$ ; Table 4). Furthermore, in the subgroup analysis of retention time (Figure 11C), TEAS was superior to the control group in improving MBI either less than 30 min or more than 30 min (SMD = 3.67, 95CI% = 2.72 to 4.62, p < 0.00001; SMD = 1.28, 95CI% = 0.57 to 2.00, p = 0.0004,  $I^2 = 94\%$ ; Table 4).

Outcomes			Certa	Certainty assessment			No. of patients	Effect sizes Certainty	Certainty
	No. of trials	No. of Risk of trials bias	Inconsistency	Indirectness	Imprecision	Publication bias	Intervention/ Control	SMD (95% CI)	
FMA-UE	13	Serious	Serious	No serious	No serious	Undetected	432/433	SMD 1.70 (1.09,2.31)	⊕⊕⊝⊝ Low
MAS	~	Serious	Serious	No serious	No serious	Serious	275/277	SMD -1.18 (-1.79,-0.58)	⊕⊝⊝⊝ Very Low
MBI	11	Serious	Serious	No serious	No serious	Undetected	443/443	SMD 1.53 (0.85,2.20)	⊕⊕⊝⊝ Low
SMD, standard mean difference; CI, confidence interval; GRADE, Grading of Recon Risk of bias: serious, study with unclear risk of bias; Inconsistency: Serious, $P > 50\%$ .	rence; CI, confiden with unclear risk o	nce interval; GRADE of bias; Inconsistenc	SMD, standard mean difference; CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development, and Evaluation. Risk of bias: serious, study with unclear risk of bias; Inconsistency: Serious, $P > 50\%$ .	ssessment, Development, and	l Evaluation.				
Indirectness: no indirectness of evidence was found in any study.	ss of evidence was	found in any study.							

#### 3.5.4 Safety of intervention

Only one trial (Wang H. et al., 2023) mentioned the safety of TEAS intervention, and no adverse reactions were reported. All the included trials reported that patients could tolerate TEAS intervention well without obvious adverse reactions. Therefore, larger-scale RCTs are needed to further confirm and report the safety of TEAS in the treatment of upper limb dysfunction after stroke.

#### 3.5.5 Sensitivity analysis and publication bias

Sensitivity analysis was performed after sequentially excluding each study, and the recalculated summary results did not change significantly, indicating that no peripheral studies significantly affected the overall results (Figures 12A, 13A, 14A). Funnel plots and Egger's test were used to assess publication bias based on the FMA-UE, MSA, and MBI scales. The distribution of the funnel plot (Figures 12B, 14B) was asymmetrical. Egger's test showed FMA-UE (p=0.005; Figure 12C), MSA (p=0.047; Figure 13B), and MBI (p=0.008; Figure 14C), suggesting that publication bias is difficult to rule out.

#### 3.5.6 Quality of evidence

The GRADE approach was employed to assess the quality of evidence from 16 RCTs (Table 3). The analysis focused on three outcome measurements: FMA-UE improvement, MAS improvement, and MBI improvement. Overall, the quality of evidence was ranked from low to very low. The results indicated that none of the outcomes were supported by high-quality evidence; two out of three (2/3, 66.67%) outcomes had low-quality evidence, while one out of three outcomes (1/3, 33.33%) had very low-quality evidence. The main reasons for the low-quality ratings were risk of bias (ROB) and inconsistency.

# 4 Discussion

### 4.1 Summary of main findings

This meta-analysis included 16 RCTs involving 1,218 stroke patients and was conducted to investigate TEAS to the influence of the upper limb functional recovery after stroke. The findings from the meta-analysis indicate that TEAS can significantly improve upper limb motor function, spasticity, and functional independence in stroke patients compared with the control group. The results are consistent with previous research results (Tang et al., 2021). However, considering the literature, the overall quality is low, with issues such as lack of follow-up, absence of adverse reaction reports, and the case fatality rate affecting the credibility. According to the GRADE guidelines, the recommended level is "very low" to "low." This result is not very convincing, requiring a larger sample size and further evidence. In addition, the meta-analysis showed that the  $I^2$  of FMA-UE, MAS, and MBI were all greater than 50%, indicating high heterogeneity among trials. To improve the reliability of the conclusions, subgroup analysis based on control interventions and TEAS parameters (including frequency, treatment duration, and retention time) was performed to find potential sources of heterogeneity.

The trials included in this meta-analysis had differences in the control group intervention, and the treatment measures of the control group included traditional rehabilitation therapies such as

TABLE 3 GRADE of evidence of outcomes of the included trials

Publication bias: Undetected due to the number of trials less than the recommended arbitrary minimum number of 10.

Imprecision (based on sample size): Serious, n < 500 participants.

Charles - Carlesson		EAS	T - 4 - 1		Control	T - 4 - 1		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD		Mean	SD		Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chao 2017	3.07	0.98	27	2.85	1.1	28	8.0%	0.21 [-0.32, 0.74]	+
Chen 2015	13.8	8.47	20	5.82	9.01	23	7.8%	0.89 [0.26, 1.52]	
Chen 2019a	19	8.41	28	12.89	9.31	28	7.9%	0.68 [0.14, 1.22]	
Chen 2019b	26.8	9.25	26	13.14	10.77	27	7.8%	1.34 [0.74, 1.94]	
Gu 2019	17.3	3.17	21	10.8	3.59	21	7.5%	1.88 [1.15, 2.62]	
Mao 2017	13.8	8.51	26	1.78	9	26	7.8%	1.35 [0.74, 1.96]	
Peng 2015	19.15	2.75	21	5.13	3.28	20	6.4%	4.55 [3.35, 5.76]	
Tang 2015	15.73	7.76	15	7.31	7.18	16	7.5%	1.10 [0.34, 1.86]	
Wang 2023	2.53	9.8	99	-0.08	3.97	97	8.3%	0.35 [0.06, 0.63]	-
Xia 2021	18.9	4.21	24	9.2	3.63	24	7.5%	2.43 [1.67, 3.19]	
Xie 2019	18.3	6	42	5.81	4.6	40	7.9%	2.31 [1.74, 2.87]	-
Yang 2023	23.52	3.18	49	13.93	2.38	49	7.8%	3.39 [2.76, 4.01]	-
Zheng 2020	13.8	5.97	34	1.78	4.28	34	7.8%	2.29 [1.67, 2.91]	-
Total (95% CI)			432			433	100.0%	1.70 [1.09, 2.31]	◆
Heterogeneity: Tau <sup>2</sup> :	= 1 14 <sup>.</sup> C	hi <sup>z</sup> = 1	70.18	df = 12.0	P < 0.0	0001\-1	<sup>2</sup> = 93%		
Test for overall effect					,		00.0	-1	10 -5 0 5 10
i cottor citoran chect	= 0.41	V . C		/					Favours [Control] Favours [TEAS]
RE 4									

#### TABLE 4 The results of subgroup analyses.

			No. of studies	No. of patients	SMD (95% CI)	p	l <sup>2</sup>	Effect model
FMA-UE	Types of control	TEAS + CR vs. CR	10	573	1.76 (1.22, 2.30)	< 0.00001	86%	Random
	group	TEAS + CR vs. Sham TEAS + CR	3	292	1.54 (0.00, 3.09)	0.05	96%	Random
	Frequency of	Once a day	3	195	1.82 (-0.13, 3.77)	0.07	97%	Random
	TEAS	5 times per week	9	622	1.57 (0.92, 2.22)	< 0.00001	92%	Random
		6 times per week	1	48	2.43 (1.67, 3.19)	< 0.00001	/	1
	Treatment	0–4 weeks	9	529	2.09 (1.33, 2.86)	< 0.00001	92%	Random
	duration	5–8 weeks	3	140	1.01 (0.60, 1.42)	< 0.00001	24%	Random
		>8 weeks	1	196	0.35 (0.06, 0.63)	0.02	/	1
	TEAS retention	<30 min	3	188	2.58 (1.68, 3.49)	< 0.00001	80%	Random
	time	≥30 min	9	600	1.50 (0.83, 2.16)	<0.0001	92%	Random
MAS	Types of control	TEAS + CR vs. CR	6	356	-1.34 (-2.03, -0.65)	0.0001	88%	Random
	group	TEAS + CR vs. Sham TEAS + CR	1	196	-0.36 (-0.65, -0.08)	0.01	/	1
	Frequency of	Once a day	2	140	-1.68 (-3.23, -0.13)	0.03	91%	Random
	TEAS	5 times per week	5	412	-1.01 (-1.74, -0.28)	0.007	90%	Random
	Treatment	0–4 weeks	5	303	-1.51 (-2.30, -0.71)	0.0002	89%	Random
	duration	5–8 weeks	1	53	-0.56 (-1.11, -0.01)	0.04	/	1
		>8 weeks	1	196	-0.36 (-0.65, -0.08)	0.01	/	1
	TEAS retention	<30 min	2	140	-1.68 (-3.23, -0.13)	0.03	91%	Random
	time	≥30 min	4	369	-1.09 (-2.00, 0.17)	0.02	93%	Random
MBI	Types of control	TEAS + CR vs. CR	9	649	1.52 (0.84, 2.21)	< 0.0001	93%	Random
	group	TEAS + CR vs. Sham TEAS + CR	2	237	1.61 (-1.59, 4.81)	0.32	98%	Random
	Frequency of	Once a day	1	108	0.51 (0.13, 0.90)	0.009	/	1
Frequency of TEAS	5 times per week	8	610	1.48 (0.58, 2.37)	0.001	95%	Random	
		6 times per week	1	48	3.67 (2.72, 4.62)	< 0.00001	/	1
	Treatment	0–4 weeks	3	173	2.53 (0.54, 4.52)	0.01	95%	Random
	duration	5–8 weeks	5	289	1.17 (0.39, 1.94)	0.003	88%	Random
		>8 weeks	3	299	2.18 (1.03, 3.32)	0.0002	92%	Random
	TEAS retention	<30 min	1	48	3.67 (2.72, 4.62)	< 0.00001	/	1
	time	≥30 min	8	687	1.28 (0.57, 2.00)	0.0004	94%	Random

CR, Conventional Rehabilitation; TEAS, Transcutaneous electrical acupoint stimulation; /, not mention; FMA-UE, Fugl-Meyer Assessment of the upper extremity; MAS, Modified Ashworth Scale; MBI, Modified Barthel Index.





FIGURE 5

Subgroup analysis of FMA-UE based on TEAS parameters: (A) Frequency of TEAS. (B) Treatment duration. (C) TEAS retention time. neurodevelopmental therapy, exercise therapy, and occupational therapy. Traditional rehabilitation therapy is based on the "motor relearning learning theory," which promotes the reconstruction of brain motor function through repeated purposeful exercise training (Dimyan and Cohen, 2011). Studies have confirmed that stroke patients often have multiple functional disorders, and taskoriented training and sensory stimulation of TEAS are complementary to each other, which can enhance the rehabilitation effect (Zhao et al., 2015). This is consistent with our results that treatment with the addition of TEAS significantly improved FMA-UE, MAS, and MBI scores compared with conventional rehabilitation alone. However, TEAS treatment did not significantly improve FMA and MBI compared with sham TEAS. This negative result is consistent with a previous TEAS study with a similar design (Alwhaibi et al., 2021). The prevalent methods for sham TEAS underwent identical settings and manipulations as those in the TEAS group, with the exception that the wire connecting the electrode pads to the TEAS stimulator was severed, thereby preventing any current from being delivered. Alwhaibi et al. (2021) compared the effects of task-specific training (TST) combined with TEAS (applied to LI4 and LI11) and sham TEAS combined with TST on upper limb movement in patients with chronic stroke. The results showed that patients in both groups improved significantly after treatment. However, when the two groups were compared, there was no significant improvement in the FMA-UE score after treatment. Even though sham TEAS is designed to have no therapeutic effect, it may still produce unintended consequences. Participants might perceive an improvement due to the placebo effect, which refers to the beneficial outcomes generated by an inactive or ineffective treatment. The experience of receiving stimulation, regardless of its sham nature, could lead to habituation or learning effects, potentially influencing participants' behavior and performance on the FMA-UE and BMI assessments. Furthermore, participants who believe they are undergoing treatment may become more attuned to their movement abilities, which could affect their performance.

TEAS stimulation parameters such as frequency, treatment duration, and retention time may significantly affect the

Church and Carls and an		TEAS	Tetel		Control	Tetel		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	lotal	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen 2015	20.75	10.34	20	13.04	12.7	23	9.1%	0.65 [0.03, 1.27]	
Chen 2019a	16.43	11.19	28	14.11	11.19	28	9.3%	0.20 [-0.32, 0.73]	+
Chen 2019b	24.23	13.02	26	13.15	9.79	27	9.2%	0.95 [0.38, 1.52]	-
Jia 2018	39.16	7.35	54	22.47	6.88	54	9.4%	2.33 [1.84, 2.82]	+
Peng 2015	29.83	4.55	21	14.57	4.58	20	8.2%	3.28 [2.31, 4.24]	
Tang 2015	27.8	7.52	15	17.94	7.08	16	8.7%	1.32 [0.53, 2.10]	
Wang 2023	18.76	14.02	99	18.57	18.05	97	9.7%	0.01 [-0.27, 0.29]	+
Xia 2021	17	1.88	24	9.1	2.33	24	8.2%	3.67 [2.72, 4.62]	
Xie 2019	23.81	6	42	5.81	4.6	40	9.0%	3.32 [2.65, 4.00]	
Yan 2019	25.73	7.76	60	17.31	7.18	60	9.6%	1.12 [0.73, 1.50]	+
Yu 2020	13.1	11.5	54	7	12.1	54	9.6%	0.51 [0.13, 0.90]	+
Total (95% CI)			443			443	100.0%	1.53 [0.85, 2.20]	◆
Heterogeneity: Tau <sup>2</sup>	= 1.20; C	hi² = 18	9.25. di	f = 10 (F	< 0.00	001); I <sup>z</sup>	= 95%		
Test for overall effect									-10 -5 0 5 10
			,						Favours [Control] Favours [TEAS]




intervention's efficacy. In terms of TEAS frequency, the 5/6 times per week treatment was superior to the control group in improving FMA-UE and MBI scores. In contrast, the once-a-day treatment was more effective in improving MAS. The possible explanation is that the effect of relieving spasticity is not sustainable due to the gradual weakening of the effector substance with the prolongation of the treatment interval (Yin et al., 2022). Regarding the duration of treatment, TEAS was superior to the control group in improving FMA-UE, MAS, and MBI scores in 0-4 weeks, 5-8 weeks, and more than 8 weeks. However, the improvement effect was most obvious during 0-4 weeks, which may be the most obvious response of the body at this effective stimulation amount. A previous study (Dimitrijević et al., 1972) suggested that regular and continuous electrical stimulation for a long time could lead to stimulation tolerance but could not cause stimulation of the motor area of the cerebral cortex (M1). For the retention time of TEAS, whether less than 30 min or more than 30 min, TEAS was superior to the control group in improving FMA-UE, MAS, and MBI scores. The study of Laddha (Laddha et al., 2015) showed that transcutaneous electrical stimulation for 30 min or 60 min for 3 weeks was effective on spasticity of lower limbs and walking ability, and there was no significant difference in efficacy. However, the lack of standardization of TEAS parameters is the limitation of its clinical treatment, and more RCTs with rigorous designs based on the differences in TEAS parameters are needed to explore the best TEAS regimen.


A total of six acupoints were included across 16 RCTs, with TE5 (Waiguan, used 14 times) and LI10 (Shousanli, used 13 times) being the most common. From the anatomical point of view, the main muscles under TE5 (Waiguan) are the extensor of the little finger, the extensor of the long thumb, and the extensor of the index finger. Stimulation is beneficial for improving the adverse movement of the wrist joint and promoting the extension of the thumb and index finger. The main muscles under the acupoint LI10 (Shousanli) are extensor carpi radialis longus, extensor carpi radialis brevis, and supinator. The forearm supination can be promoted by stimulating the acupoint, and the spasm can be relieved. TEAS can exert the effects of electrical stimulation and acupoints to promote the recovery of limb function after a stroke (Lim et al., 2023; Zhang et al., 2018).

### 4.2 Mechanisms of TEAS

A related study (Wang D. et al., 2023) has shown that the possible mechanism of limb spasticity and motor dysfunction is that the corresponding cortex of the brain is damaged after stroke, blocking its nerve conduction pathway, resulting in the reduction of local cerebral blood flow and the damage of neuromuscular innervation. TEAS can stimulate and contract the paralyzed muscles of limbs so that they can input information impulses to the nerve center, improve the excitability of relevant brain functional nerve areas, and promote the recovery of neuronal function (Li et al., 2022). Ischemia and hypoxia of brain tissue are the pathological basis of ischemic stroke. Studies have shown that TEAS, by adjusting the SIRT1/FOXO3a and SIRT1/BRCC3/NLRP3 signaling pathways following ischemic stroke, inhibits cell apoptosis, oxidative stress, and inflammation of the nerve to reduce brain damage (Tan et al., 2024) and accelerates the recovery of neurons and some functional metabolism (Nelles et al., 2001). In addition, TEAS can inhibit the TLR4/MyD88/NF-кB pathway, reduce ischemic brain damage after stroke, inhibit inflammation, cell death, and microglia activation (Wu et al., 2023), improve the motor neurons in spinal cord downlink control function, and reduce excessive muscle tone. Another study of TEAS in the treatment of upper limb spastic paralysis showed that TEAS had a significant effect on the excitability of motor-evoked potential in the affected cerebral hemisphere of stroke patients, which was speculated to be related to the enhancement of local cerebral cortical excitability through motor and sensory transduction pathways (Zhang et al., 2013).



	-	TEAS		0	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.2.1 TEAS+CR vs. (	CR .								
Chen 2015	20.75	10.34	20	13.04	12.7	23	9.1%	0.65 [0.03, 1.27]	
Chen 2019a	16.43	11.19	28	14.11	11.19	28	9.3%	0.20 [-0.32, 0.73]	+
Chen 2019b	24.23	13.02	26	13.15	9.79	27	9.2%	0.95 [0.38, 1.52]	
Jia 2018	39.16	7.35	54	22.47	6.88	54	9.4%	2.33 [1.84, 2.82]	+
Tang 2015	27.8	7.52	15	17.94	7.08	16	8.7%	1.32 [0.53, 2.10]	
Xia 2021	17	1.88	24	9.1	2.33	24	8.2%	3.67 [2.72, 4.62]	
Xie 2019	23.81	6	42	5.81	4.6	40	9.0%	3.32 [2.65, 4.00]	-
Yan 2019	25.73	7.76	60	17.31	7.18	60	9.6%	1.12 [0.73, 1.50]	+
Yu 2020	13.1	11.5	54	7	12.1	54	9.6%	0.51 [0.13, 0.90]	+
Subtotal (95% CI)			323			326	82.1%	1.52 [0.84, 2.21]	•
Test for overall effec		•	0001)						
Peng 2015	18.76	14.02	99	18.57	18.05	97	9.7%	0.01 [-0.27, 0.29]	+
Wang 2023	29.83	4.55	21	14.57	4.58	20	8.2%	3.28 [2.31, 4.24]	
Subtotal (95% CI)			120			117	17.9%	1.61 [-1.59, 4.81]	
Heterogeneity: Tau <sup>2</sup> Test for overall effec				= 1 (P <	0.0000	1); I² = 9	38%		
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> Test for overall effec	t: Z = 4.44	(P ≤ 0.	00001)	·		001); l²		1.53 [0.85, 2.20] + -1	10 -5 0 5 10 Favours [Control] Favours [TEAS]
			2.00.0		0.007		-		
Test for subaroup di									



# 4.3 Strengths and limitations


This review has some strengths. Our study includes the recent trial and comprehensive analysis of TEAS on upper limb function after stroke. We employed sensitivity analysis and subgroup analysis based on the different control groups and TEAS parameters (frequency, duration, and retention time) to investigate the sources of heterogeneity and assess the stability of our findings. In addition, funnel plots and Egger's test were employed to evaluate the potential for publication bias. However, this review has some limitations. First, the studies included in this analysis were not registered as clinical trials and did not provide details on sample size calculations. Second, the overall methodological quality

Study or Subgroup	TI Mean	EAS SD T	otal N		ntrol SD T	otal V		Std. Mean Difference IV, Random, 95% Cl		Std. Mean Difference IV, Random, 95% Cl
1.4.1 Once a day										
Chao 2017 Gu 2019	3.07 17.3			2.85 10.8	1.1 3.59	28 21	8.0% 7.5%	0.21 [-0.32, 0.74] 1.88 [1.15, 2.62]		-
Yang 2023	23.52				2.38	49	7.8%	3.39 [2.76, 4.01]		
Subtotal (95% CI)			97				23.3%	1.82 [-0.13, 3.77]		
Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2				2 (P < (	1.00001	); l* = 9	7%			
			· /							
1.4.2 5 times per weel Chen 2015	13.8	8.47	20	5.82	9.01	23	7.8%	0.89 [0.26, 1.52]		
Chen 2019a	19		28 1		9.31	28	7.9%	0.68 [0.14, 1.22]		-
Chen 2019b	26.8 13.8		26 1		0.77	27	7.8%	1.34 [0.74, 1.94]		
Mao 2017 Peng 2015	13.8			1.78 5.13	9 3.28	26 20	7.8% 6.4%	1.35 [0.74, 1.96] 4.55 [3.35, 5.76]		
	15.73				7.18	16	7.5%	1.10 [0.34, 1.86]		
Wang 2023	2.53	9.8			3.97	97	8.3%	0.35 [0.06, 0.63]		-
Xie 2019 Zheng 2020	18.3 13.8	6 5.07		5.81 1.78	4.6 4.28	40 34	7.9% 7.8%	2.31 [1.74, 2.87] 2.29 [1.67, 2.91]		1 I I
Subtotal (95% CI)	15.0		311	1.70			69.2%	1.57 [0.92, 2.22]		◆
Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2		i² = 94.8	i6, df=	8 (P < 0						
		(F < 0.0	0001)							
1.4.3 6 times per weel Xia 2021	د 18.9	4.21	24	9.2	3.63	24	7.5%	2.43 [1.67, 3.19]		
Subtotal (95% CI)			24			24	7.5%	2.43 [1.67, 3.19]		◆
Heterogeneity: Not app Test for overall effect: 2		(P < 0.0	0001)							
Total (95% CI)			432			433 1	00.0%	1.70 [1.09, 2.31]		•
Heterogeneity: Tau <sup>2</sup> = 1		i² = 170	.18, df :	= 12 (P					-10	-5 0 5 10
Test for overall effect: 2 Test for subgroup diffe				= 2 (P -	: 0.24\	² = 20 ·	896			-5 U 5 IU Favours [Control] Favours [TEAS]
B	rences.	0111 - 2		-20-	- 0.24).	- 20.	0.00			
		EAS			ntrol			Std. Mean Difference		Std. Mean Difference
Study or Subgroup 1.5.1 0 - 4 weeks	Mean		fotal I			Total V		IV, Random, 95% Cl		IV, Random, 95% CI
Chao 2017 Chen 2015	3.07 13.8		27 20	2.85 5.82	1.1 9.01	28 23	8.0% 7.8%	0.21 [-0.32, 0.74] 0.89 [0.26, 1.52]		-
Gu 2019 Mao 2017	17.3 13.8		21 26	10.8 1.78	3.59 9	21 26	7.5% 7.8%	1.88 [1.15, 2.62] 1.35 [0.74, 1.96]		+
Peng 2015	19.15	2.75	21	5.13	3.28	20	6.4%	4.55 [3.35, 5.76]		
Xia 2021 Xie 2019	18.9 18.3	4.21 6	24 42	9.2 5.81	3.63 4.6	24 40	7.5% 7.9%	2.43 [1.67, 3.19] 2.31 [1.74, 2.87]		+
Yang 2023	23.52			3.93	2.38	49	7.8%	3.39 [2.76, 4.01]		-
Zheng 2020 Subtotal (95% CI)	13.8	5.97	34 264	1.78	4.28	34 265	7.8% 68.4%	2.29 [1.67, 2.91] 2.09 [1.33, 2.86]		•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:				8 (P <	0.00001	); I <sup>2</sup> = 9	2%			
1.5.2 5 - 8 weeks			,							
Chen 2019a		8.41	28 1		9.31	28	7.9%	0.68 [0.14, 1.22]		+
Chen 2019b Tang 2015	26.8 15.73			3.14 1 7.31	7.18	27 16	7.8% 7.5%	1.34 [0.74, 1.94] 1.10 [0.34, 1.86]		
Subtotal (95% CI)			69		070.17		23.3%	1.01 [0.60, 1.42]		•
Heterogeneity: Tau <sup>=</sup> = Test for overall effect:				2 (P = 0	.27); 1*=	24%				
1.5.3 > 8 weeks										-
Wang 2023 Subtotal (95% CI)	2.53	9.8	99 99	-0.08	3.97	97 97	8.3% 8.3%	0.35 [0.06, 0.63] 0.35 [0.06, 0.63]		•
Heterogeneity: Not ap										
Test for overall effect:	2 = 2.41	(P = 0.0						1 70 61 00 0 01		•
Total (95% CI) Heterogeneity: Tau <sup>2</sup> =					< 0.000		1 <b>00.0%</b> = 93%	1.70 [1.09, 2.31]	-10	
Test for overall effect: Test for subaroup diff					o < 0.00	01). I <sup>2</sup> =	90.4%			avours [Control] Favours [TEAS]
C										
		TEAS	<b>T</b> , 4 - 1		Control			Std. Mean Differenc		Std. Mean Difference
Study or Subgroup 1.6.1 < 30 min	Mea	n SD	rotal	Mean	SD	rotal	Weigh	nt IV, Random, 95%	CI	IV, Random, 95% Cl
Gu 2019		3 3.17	21							+
Xia 2021 Yang 2023		9 4.21 2 3.18	24 49	9.2 13.93						
Subtotal (95% CI)			94			94	24.99			▲
Heterogeneity: Tau <sup>a</sup> Test for overall effec					0.007)	; I² = 80	1%			
				•/						
<b>1.6.2 ≥ 30 min</b> Chao 2017	3.0	7 0.98	27	2.85	1.1	28	8.69	% 0.21 [-0.32, 0.7	74]	+
Chen 2019a	1	9 8.41	28	12.89	9.31	28	8.69	6 0.68 [0.14, 1.2	22]	+
Chen 2019b Mag 2017		8 9.25			10.77					
Mao 2017 Peng 2015		8 8.51 5 2.75	26 21							
Tang 2015		3 7.76	15	7.31						
Wang 2023 Via 2010	2.5		99							Ť
Xie 2019 Zheng 2020		9 4.21 8 5.97	24 34	9.2 1.78						-
Subtotal (95% CI)			300			300	75.19			◆
Heterogeneity: Tauª Test for overall effec					< 0.000	)01); I²:	= 92%			
		-		/			405			•
Total (95% CI) Heterogeneity: Tau <sup>a</sup>	= 1.25	Chi <sup>2</sup> = 1	394 64.64.	df = 11	(P < ∩ ∩		100.09 I <sup>2</sup> = 93%		-+	
Test for overall effect									-10	0 -5 0 5 10 Favours [Control] Favours [TEAS]
Test for subaroup d										

FIGURE 11

Subgroup analy S parameters: **(A)** Frequency of EAS. **(B)** Trea on. **(C)** <sup>-</sup>

Study or Subgroup	TEAS Mean SD	Total Mean	Control SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
3.4.1 Once a day Yu 2020 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect:		54 7 54 009)	12.1	54 54	10.5% <b>10.5</b> %	0.51 [0.13, 0.90] <b>0.51 [0.13, 0.90]</b>	•
3.4.2 5 times per wee		~					
Chen 2015 Chen 2019a	20.75 10.34 16.43 11.19	20 13.04 28 14.11		23 28	10.1% 10.3%	0.65 [0.03, 1.27] 0.20 [-0.32, 0.73]	- F
Chen 2019b Jia 2018	24.23 13.02 39.16 7.35	26 13.15 54 22.47		27 54	10.2% 10.3%	0.95 [0.38, 1.52] 2.33 [1.84, 2.82]	+ +
Peng 2015	29.83 4.55	21 14.57	4.58	20	9.2%	3.28 [2.31, 4.24]	
Tang 2015 Wang 2023	27.8 7.52 18.76 14.02	15 17.94 99 18.57		16 97	9.7% 10.6%	1.32 [0.53, 2.10] 0.01 [-0.27, 0.29]	+
Xie 2019 Subtotal (95% CI)	23.81 6	42 5.81 305	4.6	40 305	9.9% <b>80.3</b> %	3.32 [2.65, 4.00] 1.48 [0.58, 2.37]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect		1.92, df = 7 (P	< 0.0000			110 [0100] 2101]	
3.4.3 6 times per wee							
Xia 2021 Subtotal (95% CI)	17 1.88	24 9.1 24	2.33	24 24	9.3% <b>9.3</b> %	3.67 [2.72, 4.62] 3.67 [2.72, 4.62]	
Heterogeneity: Not ap Test for overall effect						5161 [Lii Li, 1162]	
Total (95% CI)		383			100.0%	1.58 [0.80, 2.35]	
Heterogeneity: Tau² = Test for overall effect:	Z = 3.99 (P < 0.1	0001)		,,			-10 -5 0 5 10 Favours [Control] Favours [TEAS]
Test for subaroup diff	erences: Chi <sup>z</sup> =	37.45. df = 2 (	P < 0.000	001). F	= 94.7%		
B	TEAS		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup 3.5.1 0 - 4 weeks		Total Mean		Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen 2015	20.75 10.34	20 13.04		23	9.3%	0.65 [0.03, 1.27]	+
Xia 2021 Xie 2019	17 1.88 23.81 6	24 9.1 42 5.81		24 40	8.4% 9.1%	3.67 [2.72, 4.62] 3.32 [2.65, 4.00]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	2.02: Chi2 - 44	86 07 df = 2 /P a	0 00001	87	26.7%	2.53 [0.54, 4.52]	•
Test for overall effect.			0.00001	), i = 3	5.0		
3.5.2 5 - 8 weeks Chen 2019a	48.42.44.40	20 1111	44.40	28	0.50	0 20 1 0 22 0 721	1
Chen 2019b	16.43 11.19 24.23 13.02	28 14.11 26 13.15	9.79	27	9.5% 9.4%	0.20 [-0.32, 0.73] 0.95 [0.38, 1.52]	+
Peng 2015 Tang 2015	29.83 4.55 27.8 7.52	21 14.57 15 17.94		20 16	8.3% 8.8%	3.28 [2.31, 4.24] 1.32 [0.53, 2.10]	
Yu 2020 Subtotal (95% CI)	13.1 11.5	54 7 144	12.1	54 145	9.7% 45.7%	0.51 [0.13, 0.90] 1.17 [0.39, 1.94]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect		.32, df = 4 (P <	0.00001				
3.5.3 > 8 weeks							
Jia 2018 Wang 2023	39.16 7.35 29.83 4.55	54 22.47 21 14.57		54 20	9.5% 8.3%	2.33 [1.84, 2.82] 3.28 [2.31, 4.24]	+
Yan 2019	25.73 7.76	60 17.31		60	9.7%	1.12 [0.73, 1.50]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			0.00001	134 ); I² = 9	<b>27.6%</b> 2%	2.18 [1.03, 3.32]	•
Total (95% CI)		365		366	100.0%	1.82 [1.14, 2.50]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	Z = 5.26 (P < 0.1)	00001)					-10 -5 0 5 10 Favours [Control] Favours [TEAS]
Test for subaroup diff	erences: Uni <sup>+</sup> =	3.01. df = 2 (F	·= 0.22).	r= 33.	6%		
С	TEAS		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup 3.6.1 < 30 min	Mean SD	Total Mean			Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Xia 2021 Subtotal (95% CI)	17 1.88	24 9.1 24	2.33	24 24	10.1% <b>10.1</b> %	3.67 [2.72, 4.62] 3.67 [2.72, 4.62]	•
Heterogeneity: Not ap Test for overall effect:		00001)					
3.6.2 ≥ 30 min							
Chen 2019a Chen 2019b	16.43 11.19 24.23 13.02	28 14.11 26 13.15			11.4% 11.3%	0.20 [-0.32, 0.73] 0.95 [0.38, 1.52]	<b>*</b>
Peng 2015 Tang 2015	29.83 4.55 27.8 7.52	21 14.57 15 17.94	4.58	20	10.1% 10.7%	3.28 [2.31, 4.24] 1.32 [0.53, 2.10]	
Wang 2023	18.76 14.02	99 18.57	18.05	97	11.9%	0.01 [-0.27, 0.29]	+
Xie 2019 Yan 2019	23.81 6 25.73 7.76	42 5.81 60 17.31		40 60	11.0% 11.7%	3.32 [2.65, 4.00] 1.12 [0.73, 1.50]	+
Yu 2020 Subtotal (95% CI)	13.1 11.5	54 7 345	12.1	54 342	11.7% 89.9%	0.51 [0.13, 0.90] 1.28 [0.57, 2.00]	
Heterogeneity: Tau² = Test for overall effect		0.01, df = 7 (P	< 0.0000				
Total (95% CI)		369			100.0%	1.53 [0.78, 2.28]	•
Heterogeneity: Tau <sup>2</sup> =	1.22; Chi <sup>2</sup> = 15	5.53, df = 8 (P	< 0.0000	1); I <sup>z</sup> =	95%		-10 -5 0 5 10
Test for overall effect.							Favours [Control] Favours [TEAS]



of all the analyzed studies was low, and allocation concealment and blinding were not described in detail. Two studies had more than 5% missing outcome data, which may have been subject to implementation and measurement biases. Third, only studies published in Chinese and English were included, which may introduce publication bias. Finally, adverse events were rarely reported in the original study, and safety concerns cannot be assured. Therefore, we interpret the results cautiously.

# 5 Conclusion


Existing evidence suggests that TEAS can improve upper limb motor function and spasticity in stroke patients and improve daily life abilities. The improvement in upper limb motor function appears to have a dosedependent relationship with the frequency, duration, and retention time of the TEAS intervention. However, these findings should be interpreted cautiously due to the restricted number and low methodological quality of the included trials. High-quality, large-sample, multi-center trials are needed to further confirm these preliminary findings.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

# Author contributions

XW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. LY: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing, Conceptualization, Formal analysis, Supervision, Validation. YW: Data curation, Investigation, Methodology, Supervision, Writing – review & editing. HZ: Data curation, Formal analysis, Investigation, Writing – review & editing,



Validation. SZ: Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing, Validation. JWu: Data curation, Methodology, Writing – review & editing. SF: Investigation, Supervision, Validation, Writing – review & editing. ZL: Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing, Supervision. HL: Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing. JWa: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was financially supported by the National Science Foundation of China (No. 82274674). Tianjin's Second Batch of High-Level Talent Selection and Training Program in the Health and Medical Sector - Haihe Medical Scholars" and "Clinical Efficacy of Abdominal Massage in the Treatment of Spasmodic Torticollis and Its Correlation with Gut Microbiota.

# Acknowledgments

We are very appreciative of all the authors who participated in this study.

# References

Alwhaibi, R. M., Mahmoud, N. F., Zakaria, H. M., Ragab, W. M., Awaji, N. N. A., Elzanaty, M. Y., et al. (2021). Therapeutic efficacy of transcutaneous electrical nerve stimulation Acupoints on motor and neural recovery of the affected upper extremity in chronic stroke: a sham-controlled randomized clinical trial. *Healthcare* 9:20. doi: 10.3390/healthcare9050614

Chao, M. (2016). Stndy on the effect of transcutaneous electrical acupoint stimulation Baxie point in teating hand dysfunction for stroke patients with spasticity (thesis). Nanjing, JS: Nanjing University of Traditional Chinese Medicine.

Chen, Y., Tian, J., Xie, B. J., Xu, Y. M., Tang, C. Z., Zhang, X. L., et al. (2015). Effects of transcutaneous electrical acupoint stimulation treatment in stroke survivors with upper dysfunction. *Chinese J. Rehabil. Med.* 30, 454–457. doi: 10.3969/j. issn.1001-1242.2015.05.009

Chen, Y., Wang, H. W., Xiang, Y. Z., Sun, X. Y., Dong, Q. L., Wang, Y. Y., et al. (2019a). Short-term effectiveness of community-based low frequency transcutaneous electric acupoint stimulation on upper limb and hand function rehabilitation in stroke patients. *Chinese J. Rehabil.* 34:4.

Chen, Y., Wang, H. W., Xiang, Y. Z., Wang, X. W., Zhao, K., Dou, X. Y., et al. (2019b). Effects of low frequency transcutaneous electric Acupoint stimulation on upper limbs and hands function for chronic stroke patients. *Chin. J. Rehabil. Theory Pract.* 24, 1371–1375. doi: 10.3969/j.issn.1006-9771.2018.12.002

Chi, Y. L., Zhang, W. L., Yang, F., Su, F., and Zhou, Y. K. (2019). Transcutaneous electrical Acupoint stimulation for improving postoperative recovery, reducing stress and inflammatory responses in elderly patient undergoing knee surgery. *Am. J. Chin. Med.* 47, 1445–1458. doi: 10.1142/S0192415X19500745

Coscia, M., Wessel, M. J., Chaudary, U., Millán, J. D. R., Micera, S., Guggisberg, A., et al. (2019). Neurotechnology-aided interventions for upper limb motor rehabilitation in severe chronic stroke. *Brain* 142, 2182–2197. doi: 10.1093/brain/awz181

Dawson, J., Liu, C. Y., Francisco, G. E., Cramer, S. C., Wolf, S. L., Dixit, A., et al. (2021). Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. *Lancet* 397, 1545–1553. doi: 10.1016/S0140-6736(21)00475-X

Dimitrijević, M. R., Faganel, J., Dimitrijević, M., Nathan, P. W., and Trontelj, J. K. (1972). Habituation: effects of regular and stochastic stimulation. *J. Neurol. Neurosurg. Psychiatry* 35, 234–242. doi: 10.1136/jnnp.35.2.234

Dimyan, M. A., and Cohen, L. G. (2011). Neuroplasticity in the context of motor rehabilitation after stroke. *Nat. Rev. Neurol.* 7, 76–85. doi: 10.1038/nrneurol.2010.200

Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in metaanalysis detected by a simple, graphical test. *BMJ* 315, 629-634. doi: 10.1136/ bmj.315.7109.629

GBD 2021 Causes of Death Collaborators (2024). Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. *Lancet* 403, 2100–2132. doi: 10.1016/S0140-6736(24)00367-2

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2024.1438994/ full#supplementary-material

Gu, Z. W., Lei, B., Deng, W. Z., and Zhang, J. K. (2019). To observe the application effect of transcutaneous electrical acupoint stimulation in community patients with hand dysfunction after stroke. *Chin. J. Clin. Rational Drug Use* 12:2.

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 336, 924–926. doi: 10.1136/bmj.39489.470347.AD

Higgins, J. P. T., Altman, D. G., Gtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343:d5928. doi: 10.1136/bmj.d5928

Higgins, J. P. T., and Thompson, S. G. (2002). Quantifying heterogeneity in a metaanalysis. *Stat. Med.* 21, 1539–1558. doi: 10.1002/sim.1186

Huang, H. Y., Bach, J. R., Sharma, H. S., Chen, L., Wu, P., Sarnowska, A., et al. (2024). The 2023 yearbook of neurorestoratology. *J. Neuro Oncol.* 12:100136. doi: 10.1016/j. jnrt.2024.100136

Jia, J., Zhong, J. B., and Liu, J. (2018). Clinical study of TEAS coordinated with basic rehabilitation training on hand dysfunction after stroke. *J. Clin. Acupunct Moxibustion.* 34:4.

Julie, B., Erin, G., Liam, J., and Peter, L. (2017). Early rehabilitation after stroke. Curr. Opin. Neurol. 30, 48–54. doi: 10.1097/WCO.000000000000404

Laddha, D., Ganesh, G. S., Pattnaik, M., Mohanty, P., and Mishra, C. (2015). Effect of transcutaneous electrical nerve stimulation on plantar flexor muscle spasticity and walking speed in stroke patients. *Physiother. Res. Int.* 21, 247–256. doi: 10.1002/pri.1638

Langhammer, B., and Stanghelle, J. K. (2011). Can physiotherapy after stroke based on the Bobath concept result in improved quality of movement compared to the motor relearning programme. *Physiother. Res. Int.* 16, 69–80. doi: 10.1002/pri.474

Li, J. L., Hao, M. D., Liu, M. N., Wang, J., Gao, D. Y., Han, S., et al. (2022). Transcutaneous electrical Acupoint stimulation pretreatment alleviates cerebral ischemia-reperfusion injury in rats by modulating microglia polarization and Neuroinflammation through Nrf2/HO-1 signaling pathway. *Neurochem. Res.* 48, 862–873. doi: 10.1007/s11064-022-03797-5

Lim, S. M., Go, E., Lee, J., Lee, G. E., Kim, E. J., and Son, C. (2023). Improving upper limb spasticity in patients with stroke by Electroacupuncture therapy: a pre-and posttreatment study. *J. Acupunct. Meridian Stud.* 16, 248–254. doi: 10.51507/j. jams.2023.16.6.248

Liu, X. H., Huai, J., Gao, J., Zhang, Y., and Yue, S. W. (2017). Constraint-induced movement therapy in treatment of acute and sub-acute stroke: a meta-analysis of 16 randomized controlled trials. *Neural Regen. Res.* 12, 1443–1450. doi: 10.4103/1673-5374.215255

Ma, Q. F., Li, R., Wang, L. J., Yin, P., and Yang, Y. (2021). Temporal trend and attributable risk factors of stroke burden in China, 1990–2019: an analysis for the global burden of disease study 2019. *Lancet Public Health* 6, e897–e906. doi: 10.1016/S2468-2667(21)00228-0

Mao, Z. F., Wang, X. L., Yang, R. C., Xu, L. X., Zhao, Y. R., and Yu, L. H. (2017). Effect of transcutaneous electrical acupoint stimulation in patients with hand dysfunction after stroke. *Mod. Pract. Med.* 29:2. doi: 10.3969/j.issn.1671-0800.2017.12.010

Meng, L., Jiang, X., Qin, H., Fan, J., Zeng, Z., Chen, C., et al. (2022). Automatic upper-limb Brunnstrom recovery stage evaluation via daily activity monitoring. *IEEE Trans. Neural Syst. Rehabil. Eng.* 30, 2589–2599. doi: 10.1109/TNSRE.2022.3204781

Muller, C. O., Faity, G., Muthalib, M., Perrey, S., Dray, G., Xu, B., et al. (2024). Brainmovement relationship during upper-limb functional movements in chronic post-stroke patients. *J. Neuroeng. Rehabil.* 21:188. doi: 10.1186/s12984-024-01461-3

Nelles, G., Jentzen, W., Jueptner, M., Müller, S., and Diener, H. C. (2001). Arm training induced brain plasticity in stroke studied with serial positron emission tomography. *NeuroImage* 13, 1146–1154. doi: 10.1006/nimg.2001.0757

Nogueira, N., Parma, J. O., Leão, S., Sales, I. S., Macedo, L. C., Galvão, A., et al. (2021). Mirror therapy in upper limb motor recovery and activities of daily living, and its neural correlates in stroke individuals: a systematic review and meta-analysis. *Brain Res. Bull.* 177, 217–238. doi: 10.1016/j.brainresbull.2021.10.003

Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., and Mckenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 372:n160. doi: 10.1136/bmj.n160

Pan, Y. Y., Shao, Y. F., Chi, Z. H., Jin, S. H., and Wang, J. L. (2023). Transcutaneous electrical Acupoint stimulation accelerates the recovery of patients undergoing laparoscopic myomectomy: a randomized controlled trial. *J. Pain Res.* 16, 809–819. doi: 10.2147/jpr.S399249

Peng, Y., Zhang, J., Su, C. C., Zhang, S. X., Wen, L. L., and Chen, Y. J. (2015). Effects of transcutaneous acupoint electrical stimulation on upper limb function and motor evoked potential in stroke patients. *Chinese J. Rehabil. Med.* 30:571.

Pollock, A., Farmer, S. E., Brady, M. C., Langhorne, P., Mead, G. E., Mehrholz, J., et al. (2014). Interventions for improving upper limb function after stroke. *Cochrane Database Syst. Rev.* 2014:Cd010820. doi: 10.1002/14651858.CD010820.pub2

Sacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J., Culebras, A., et al. (2013). An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 44, 2064–2089. doi: 10.1161/STR.0b013e318296aeca

Szmit, M., Krajewski, R., Rudnicki, J., and Agrawal, S. (2023). Application and efficacy of transcutaneous electrical acupoint stimulation (TEAS) in clinical practice: a systematic review. *Adv. Clin. Exp. Med.* 32, 1063–1074. doi: 10.17219/acem/159703

Tan, Z. X., Dong, F., Wu, L. Y., Xu, G. Y., and Zhang, F. (2024). Transcutaneous electrical acupoint stimulation attenuated neuroinflammation and oxidative stress by activating SIRT1-induced signaling pathway in MCAO/R rat models. *Exp. Neurol.* 373:114658. doi: 10.1016/j.expneurol.2023.114658

Tang, C. Z., Li, C. Y., Zhang, X. L., Wang, J. Y., Liu, Z. L., He, Z. J., et al. (2015). Effects of low frequency transcutaneous electric acupoint stimulation on hand and upper extremity dysfunction post stroke. *Chin. J. Rehabil. Theory Pract.* 21:4. doi: 10.3969/j. issn.1006-9771.2015.03.002

Tang, Y. Q., Wang, L. J., He, J. X., Xu, Y. P., Huang, S. J., and Fang, Y. (2021). Optimal method of electrical stimulation for the treatment of upper limb dysfunction after stroke: a systematic review and Bayesian network Meta-analysis of randomized controlled trials. *Neuropsychiatr. Dis. Treat.* 17, 2937–2954. doi: 10.2147/NDT.S332967

Tang, Q., Yang, X., Sun, M., He, M., Sa, R., Zhang, K., et al. (2024). Research trends and hotspots of post-stroke upper limb dysfunction: a bibliometric and visualization analysis. *Front. Neurol.* 15:1449729. doi: 10.3389/fneur.2024.1449729

Thrane, G., Askim, T., Stock, R., Indredavik, B., Gjone, R., Erichsen, A., et al. (2015). Efficacy of constraint-induced movement therapy in early stroke rehabilitation: a randomized controlled multisite trial. *Neurorehabil. Neural Repair* 29, 517–525. doi: 10.1177/1545968314558599

Tu, W. J., and Wang, L. D. (2023). China stroke surveillance report 2021. *Mil. Med. Res.* 10:33. doi: 10.1186/s40779-023-00463-x

Wang, C. L. (2024). Analysis of the effect of transcutaneous electrical stimulation of acupoints combined with rehabilitation training in the treatment of upper limb dysfunction after stroke. *J. Clin. Nurs. Res.* 8, 316–321. doi: 10.26689/jcnr.v8i6.7628

Wang, Y. J., Li, Z. X., Gu, H. Q., Zhai, Y., Zhou, Q., Jiang, Y., et al. (2022). China stroke statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for neurological diseases, the Chinese Stroke Association, National Center for chronic and non-communicable disease control and prevention, Chinese Center for Disease Control

and Prevention and institute for global neuroscience and stroke collaborations. *Stroke Vasc. Neurol.* 7, 415–450. doi: 10.1136/svn-2021-001374

Wang, D., Wang, J., Zhao, H. B., Liang, Y. H., Zhang, W. Y., Li, M. X., et al. (2023). The relationship between the prefrontal cortex and limb motor function in stroke: a study based on resting-state functional near-infrared spectroscopy. *Brain Res.* 1805:148269. doi: 10.1016/j.brainres.2023.148269

Wang, H., Xiang, Y. Z., Wang, C. K., Wang, Y. Y., Chen, S. G., Ding, L., et al. (2023). Effects of transcutaneous electrical acupoint stimulation on upper-limb impairment after stroke: a randomized, controlled, single-blind trial. *Clin. Rehabil.* 37, 667–678. doi: 10.1177/02692155221138916

Winstein, C. J., Stein, J., Arena, R., Bates, B., Cherney, L. R., Cramer, S. C., et al. (2013). Guidelines for adult stroke rehabilitation and recovery a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 47, e98–e169. doi: 10.1161/STR.00000000000000098

Wu, L. Y., Tan, Z. X., Su, L., Dong, F., Xu, G. Y., and Zhang, F. (2023). Transcutaneous electrical acupoint stimulation alleviates cerebral ischemic injury through the TLR4/ MyD88/NF-κ B pathway. *Front. Cell. Neurosci.* 17:1343842. doi: 10.3389/ fncel.2023.1343842

Xia, D. J., Xiong, X. S., Lv, Y. Q., Fan, R., and Peng, T. (2021). Effects of bilateral arm transcutaneous electrical acupoint stimulation on upper limb function for subacute stroke hemiplegic patients. *Chin. J. Rehabil. Theory Pract.* 27, 1318–1322. doi: 10.3969/j. issn.1006

Xie, J. J., Li, J. X., and Sun, Q. (2019). A randomized controlled trial of transcutaneous electrical acupoint stimulation for upper extremity dysfunction after stroke. *J. Basic Chinese Med.* 25:3.

Xu, J. M., Liu, L. Q., Li, Y. L., and Li, M. Y. (2016). Experiences of application of acupuncture in stroke rehabilitation with integrated traditional Chinese and Western medicine. *Chin. J. Rehabil. Theory Pract.* 22:4. doi: 10.3969/j.issn.1006-9771.2016.02.026

Yan, Y. L., Ding, X. M., and Lv, Y. J. (2019). Low frequency transcutaneous electrical acupoint stimulation for stroke sequelae stage hand and upper limb dysfunction. *Cardiovasc. Dis. J. Integrated Trad Chinese Western Med.* 7, 87–88. doi: 10.16282/j.cnki. cn11-9336/r.2019.12.060

Yan, T., and Hui-Chan, C. W. (2009). Transcutaneous electrical stimulation on acupuncture points improves muscle function in subjects after acute stroke: a randomized controlled trial. *J. Rehabil. Med.* 41, 312–316. doi: 10.2340/16501977-0325

Yang, L. L. (2023). Transcutaneous acupoint electrical stimulation combined rehabilitation training in the treatment of upper limb dysfunction after stroke clinical observation. *J. Prac. Tradit Chin. Med.* 39, 983–985.

Yin, C. S., Zhang, C., Meng, X. G., and Zhao, Q. (2022). Current research status on the dose-response and timeliness of acupuncture treatment for stroke. *Shanghai J. Acu Mox.* 41, 824–830. doi: 10.13460/j.issn.1005-0957.2022.08.0824

Yu, L. H., Jiang, M., and Mao, Z. F. (2020). Application of percutaneous acupoint electrical stimulation in the rehabilitation of hand dysfunction after stroke. *China Modern Doctor* 58:4.

Zhang, L., Jia, G., Ma, J., Wang, S., and Cheng, L. (2022). Short and long-term effects of robot-assisted therapy on upper limb motor function and activity of daily living in patients post-stroke: a meta-analysis of randomized controlled trials. *J. Neuroeng. Rehabil.* 19:76. doi: 10.1186/s12984-022-01058-8

Zhang, Y., Jiang, Y., Glielmi, C. B., Li, L. C., Hu, X. P., Wang, X. Y., et al. (2013). Longduration transcutaneous electric acupoint stimulation alters small-world brain functional networks. *Magn. Reson. Imaging* 31, 1105–1111. doi: 10.1016/j.mri.2013.01.006

Zhang, B., Zhu, Y. L., Jiang, C. Y., Li, C., Li, Y. Y., Bai, Y. L., et al. (2018). Effects of transcutaneous electrical Acupoint stimulation on motor functions and self-care ability in children with cerebral palsy. *J. Altern. Complement. Med.* 24, 55–61. doi: 10.1089/acm.2016.0111

Zhao, W. L., Wang, C., Li, Z. Z., Chen, L., Li, J. B., Cui, W. D., et al. (2015). Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double-blinded, multicenter, randomized controlled trial. *PLoS One* 10:e0116976. doi: 10.1371/journal.pone.0116976

Zheng, W. Y., and Mao, Z. F. (2020). Application of transcutaneous acupoint electrical stimulation in rehabilitation of elderly patients with post-stroke hand dysfunction. *China Modern Doctor.* 58:4.

Zhou, S., Guo, Z. Q., Wong, K. F., Zhu, H. L., Huang, Y. H., Hu, X. L., et al. (2021). Pathway-specific cortico-muscular coherence in proximal-to-distal compensation during fine motor control of finger extension after stroke. *J. Neural Eng.* 18:056034-. doi: 10.1088/1741-2552/ac20bc